The Impending Compliance Decision
For financial institutions (FIs) serving hemp-related businesses (HRBs), November 12, 2026, represents a definitive crossroads. On this date, new federal laws are set to take effect that will effectively prohibit the vast majority of currently formulated consumable hemp products. While legislative delays or modifications remain possible, FIs should prepare for the absence of such relief.
Beyond shifting to a 0.3% total THC standard (including THCA), the new federal definition of “hemp” introduces a restrictive 0.4 mg-per-container cap on THC and functionally similar cannabinoids. It also broadly prohibits the synthesis or conversion of cannabinoids. These restrictions cast such a wide net that they will inadvertently ban many non-intoxicating hemp products (e.g., full-spectrum CBD) alongside the intoxicating cannabinoid market the law intended to target.
This shift is more than a technical adjustment; it is a federal reclassification. Many consumable hemp products currently sold in states like Florida will be legally redefined as “marijuana,” which remains a Schedule I controlled substance under the federal Controlled Substances Act (CSA). [1] For FIs, maintaining the status quo without recalibrating compliance frameworks will expose them to heightened BSA/AML risk.
The Quandary: Florida as a Case Study
Many states that permit (or do not prohibit) consumable hemp products will not have updated their laws or regulations by the time the new federal hemp law becomes effective in November. Florida serves as a primary example of the compliance challenge ahead.
Because the 2026 Florida legislative session concluded without aligning state law with the new federal standards — and the next session will not begin until after the federal law takes effect — a significant regulatory “gap” is likely to emerge.
- State-Legal vs. Federally Non-Compliant
A Florida HRB may be in full compliance with Florida Statute § 581.217 and associated rules, yet its products may be defined as “marijuana” under the new federal definition. This creates a scenario in which products are categorized as hemp under state law but as marijuana under federal law. Where state law comes into direct conflict with federal law, federal law supersedes state law.
- The Lack of Federal Shields
Florida’s licensed medical marijuana companies (MMTCs) operate under the protection of the Rohrabacher–Farr Amendment, which prohibits the Department of Justice from using federal funds to interfere with state medical marijuana programs. Crucially, no comparable federal budget protection extends to state-compliant HRBs impacted by the 2026 reclassification.
- Enforcement Uncertainty
Following the rescission of the Cole Memorandum over eight years ago, federal enforcement policy remains at the discretion of individual U.S. Attorneys’ Offices. While historically restrained, uncertainty remains regarding how prosecutors will view the formerly “legal” hemp sector, particularly in states where regulatory frameworks are limited or where enforcement assistance is welcomed by the state.
The Compliance Framework Dilemma
Compounding these legal conflicts is the lack of updated federal guidance, a gap made even more acute for the state-licensed medical marijuana sector following its historic reclassification as a Schedule III controlled substance. Financial institutions are currently forced to rely on frameworks designed long before the hemp and marijuana industries reached their current maturity. BSA expectations regarding marijuana-related businesses (MRBs) were established over a decade ago under FIN-2014-G001 (the “2014 MRB Guidance”), while FinCEN guidance for HRBs was issued nearly six years ago under FIN-2020-G001 (the “2020 HRB Guidance”). In the absence of updated FinCEN guidance prior to the November effective date, FIs who wish to service the market are left to navigate two primary, yet imperfect, paths:
Path 1: The Challenges of Relying on Existing Hemp Guidance
To theoretically remain within the 2020 HRB Guidance framework after November 12, an FI would need to implement a significantly enhanced due diligence program. However, reliance on this guidance presents inherent difficulties:
- An Imperfect and Outdated Framework
The 2020 HRB Guidance was designed primarily for hemp cultivation and production, not the modern retail landscape of consumable hemp products. It is also anchored in the prior definition of hemp (0.3% Delta-9 THC), making it an increasingly poor fit for a regime focused on “total THC”, synthesized cannabinoids, and per-container limits.
- Intensive Diligence
Even under the 2020 HRB Guidance framework, FIs face the operational challenge of conducting due diligence on products manufactured or sold by a customer to ensure compliance with the new federal definition. This level of review is imperative: verifying that finished products – and the intermediate hemp-derived cannabinoid product used to manufacture them – meet the new specifications of “hemp” is what allows legal interstate commerce to continue without implicating the CSA. At scale, however, maintaining this degree of oversight could prove burdensome and resource-intensive, at least in the short term.
Path 2: Transitioning to the Marijuana-Related Business (MRB) Framework
If an FI determines that its HRB customers are selling products that remain state-legal but are federally non-compliant, it may consider transitioning those relationships into an MRB compliance framework under FIN-2014-G001. This approach is more burdensome for FIs, requiring heightened due diligence to ensure the customer’s activities do not implicate federal enforcement priorities. Specifically, FIs must adhere to rigorous reporting mandates, including the continuous filing of Suspicious Activity Reports (SARs) for all marijuana-related transactions, regardless of whether the activity is considered legal under state law. This transition may require new and unique internal controls to address challenges not present in traditional state-regulated cannabis markets:
- Intrastate Commerce Limitations
Even though the Cole Memo (which prioritized federal non-interference in state-legal marijuana markets) was officially rescinded by the DOJ, the 2014 MRB Guidance explicitly ties marijuana banking compliance to its eight enforcement priorities. A key priority is preventing diversion across state lines. Because the hemp industry was built on interstate commerce, FIs would face the difficult task of ensuring that newly reclassified “marijuana products” are not distributed beyond state borders. And unlike state-legal marijuana programs, the hemp industry is largely not mandated to use seed-to-sale tracking systems, further limiting an FI’s ability to verify product origin and movement.
- Short-Term Volatility with Uncertain Long-Term Viability
Certain states will choose to fold consumable hemp products into their existing adult-use marijuana programs. Not all states have that option or will take that approach in the short term, however. Individual states may update or change their laws in ways that continue to diverge from, or align with, federal law. The volatility and pace of these changes will continue to be significantly higher in the hemp sector. This requires heightened state-level compliance controls for FIs seeking to transition HRB customers to the MRB framework.
Conclusion: Preparing for Federal Hemp Law Changes in 2026
Absent legislative change, the federally permissible space for consumable hemp products is contracting significantly. Financial institutions should not wait until the November 12 deadline to evaluate their exposure with a cannabis law attorney. To determine the future of their hemp-related programs, financial institutions should consider the following:
- Scope the Regulatory Impact: Assess how federal changes will automatically reclassify much of the current hemp market including intermediate supply chain materials and finished goods, as controlled substances. FIs must determine how this shift transforms previously routine transactions into potential compliance violations.
- Audit Total Sector Exposure: Identify all touchpoints with existing customers from direct manufacturers and retailers to ancillary businesses whose services, operations, or inventory may be implicated by the new federal definitions.
- Validate Customer Adaptation: Perform due diligence to verify how existing HRB customers intend to pivot their business operations to remain compliant. This process is essential to identifying which customers meet the institution’s revised risk tolerance and compliance standards.
- Execute the “Go/No-Go” Decision: If the financial institution intends to continue servicing the sector, it must overhaul its compliance framework and develop the internal controls necessary to manage the higher-risk landscape, at least in the short term.
There are various federal legislative efforts to prevent the harsh new law from taking effect on hemp-related businesses come November. If unsuccessful, ultimately, the impending change in federal law represents a fundamental restructuring of the hemp industry. Financial institutions maintaining a nexus to the sector must proactively refine their strategic approach and compliance protocols in advance of the November 12 deadline.
[1]In April 2026, the DOJ issued a final order that immediately rescheduled only FDA-approved cannabis products and state-licensed medical marijuana to Schedule III. Consumable hemp products, when redefined under the new federal law, will be deemed non-medical marijuana. Non-medical (recreational) marijuana is currently undergoing a separate administrative rule-making process that could eventually lead to a Schedule III classification. As of now, however, non-compliant hemp products failing the new strict thresholds will default to being classified under Schedule I.
